Clinical Trial Update: Safety, Tolerability and Immunogenicity of an Inactivated Whole-cell Pneumococcal Vaccine Gamma-PN3. [Phase 1]

View source ↗

Summary

Phase 1 study evaluating safety, tolerability, and immunogenicity of Gamma-PN3, an inactivated whole-cell pneumococcal vaccine. The trial has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pneumococcal Infections

Drugs mentioned

• Gamma-PN3

Snippet

Sponsor: GPN Vaccines | Conditions: Pneumococcal Infections | Phase 1 | Status: COMPLETED